Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AVI BioPharma begins Duchenne muscular dystrophy trial
The trial will include up to nine boys with Duchenne muscular dystrophy (DMD), each of whom will receive a single intramuscular (IM) administration of the drug. Two to
The trial will include up to nine boys with Duchenne muscular dystrophy (DMD), each of whom will receive a single intramuscular (IM) administration of the drug. Two to
The approval is primarily based on the results of two randomized, controlled, multi-center clinical trials in adult patients: Champion and Reveal. In both trials, the signs and symptoms
In the primary analysis, there was no statistically significant difference in the progression-free survival (PFS) of patients receiving MyVax personalized immunotherapy compared to patients receiving the control substance.
On May 24, 2007 Naviscan filed suit against Dilon in the US District Court of California for possible patent infringement of six US patents directed to technology for
The gross proceeds, before deducting underwriting discounts and offering expenses, from the sale of the aggregate 12.34 million shares were approximately $50 million and the net proceeds, after
The Phase III clinical program for bapineuzumab is intended to provide safety and efficacy data to support the filing and approval. The Phase III study includes four randomized,
The double-blind, placebo-controlled trial is expected to require nine months to complete enrollment of approximately 390 amyotrophic lateral sclerosis (ALS) volunteers at 30 to 40 US and Canadian
Jazz and Solvay Pharmaceuticals are seeking marketing approval for the treatment of social anxiety disorder (SAD) and obsessive compulsive disorder (OCD).
The supplemental biological license application (sBLA) was submitted by Bristol-Myers Squibb Company to meet expected long-term demand for Orencia. Jung-Jin Seo, chairman and CEO of Celltrion, said: “Achieving
Once the IND is approved, VGX will conduct single ascending dose (SAD) and multiple ascending dose (MAD) Phase I studies on VGX-1027 in 2008. The company is currently